These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23076205)

  • 1. Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis.
    Modena P; Buttarelli FR; Miceli R; Piccinin E; Baldi C; Antonelli M; Morra I; Lauriola L; Di Rocco C; Garrè ML; Sardi I; Genitori L; Maestro R; Gandola L; Facchinetti F; Collini P; Sozzi G; Giangaspero F; Massimino M
    Neuro Oncol; 2012 Nov; 14(11):1346-56. PubMed ID: 23076205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.
    Ridley L; Rahman R; Brundler MA; Ellison D; Lowe J; Robson K; Prebble E; Luckett I; Gilbertson RJ; Parkes S; Rand V; Coyle B; Grundy RG;
    Neuro Oncol; 2008 Oct; 10(5):675-89. PubMed ID: 18701711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma.
    Tabori U; Ma J; Carter M; Zielenska M; Rutka J; Bouffet E; Bartels U; Malkin D; Hawkins C
    J Clin Oncol; 2006 Apr; 24(10):1522-8. PubMed ID: 16575002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
    Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.
    Chen C; Chen L; Yao Y; Qin Z; Chen H
    J Neurooncol; 2016 Mar; 127(1):43-52. PubMed ID: 26615563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
    Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
    Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
    Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
    Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nestin expression identifies ependymoma patients with poor outcome.
    Milde T; Hielscher T; Witt H; Kool M; Mack SC; Deubzer HE; Oehme I; Lodrini M; Benner A; Taylor MD; von Deimling A; Kulozik AE; Pfister SM; Witt O; Korshunov A
    Brain Pathol; 2012 Nov; 22(6):848-60. PubMed ID: 22568867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
    Korshunov A; Golanov A; Timirgaz V
    J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic marker analysis in pediatric intracranial ependymomas.
    McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
    J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
    Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
    PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP).
    Kilday JP; Mitra B; Domerg C; Ward J; Andreiuolo F; Osteso-Ibanez T; Mauguen A; Varlet P; Le Deley MC; Lowe J; Ellison DW; Gilbertson RJ; Coyle B; Grill J; Grundy RG
    Clin Cancer Res; 2012 Apr; 18(7):2001-11. PubMed ID: 22338015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review.
    Zawrocki A; Iżycka-Świeszewska E; Papierz W; Liberski PP; Zakrzewski K; Biernat W
    Folia Neuropathol; 2011; 49(2):94-102. PubMed ID: 21845537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of cell cycle/apoptosis regulators and epidermal growth factor receptor in pediatric intracranial ependymomas.
    Alexiou GA; Stefanaki K; Moschovi M; Patereli A; Prodromou N; Karentzou O
    J Child Neurol; 2011 Feb; 26(2):195-8. PubMed ID: 20713981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical markers for prognosis of ependymal neoplasms.
    Korshunov A; Golanov A; Timirgaz V
    J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of chromosome 1q gain in intracranial ependymomas.
    Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
    J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis.
    Serce NB; Boesl A; Klaman I; von Serényi S; Noetzel E; Press MF; Dimmler A; Hartmann A; Sehouli J; Knuechel R; Beckmann MW; Fasching PA; Dahl E
    BMC Cancer; 2012 Dec; 12():597. PubMed ID: 23236990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer.
    Hara H; Yamashita K; Shinada J; Yoshimura H; Kameya T
    Lung Cancer; 2001 Nov; 34(2):219-26. PubMed ID: 11679180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.